Conclusions: Standardised targeted scanning protocols starting in1st trimester will help to plan follow-up, avoid unanticipated peripartum discoveries of PA as well as reassure patients otherwise at risk based upon history of CS.
Supporting information can be found in the online version of this abstract Objectives: To report the incidence of preterm pre-eclampsia (PE) in women that fulfil the screening criteria of the NICE and ACOG and compare the incidence in those that are screen-positive and screen-negative by the FMF algorithm. Methods: This was a secondary analysis of data from the ASPRE study. The study population consisted of women with singleton pregnancies who had prospective screening for preterm-PE by the FMF algorithm that combines maternal factors and biomarkers at 11-13 weeks' gestation. We estimated the incidence of preterm-PE in those fulfilling the NICE and ACOG criteria; in these patients we then calculated the incidence of preterm-PE in those that were screen-negative relative to those that were screen-positive by the FMF algorithm. Results: A total of 34,573 women with singleton pregnancies delivering at ≥24 weeks' gestation underwent prospective screening for preterm-PE, including 239 (0.7%) cases of preterm-PE. At least one of the ACOG criteria was fulfilled in 22,287 (64.5%) of pregnancies and the incidence of preterm-PE was 0.97%; in those that was FMF screen-positive the incidence was 4.80%, in those that were screen-negative it was 0.25% and the relative incidence (RI) in FMF-negative to FMF-positive was 0.051. In 1,392 (4.0%) pregnancies ≥1 NICE high-risk criteria was fulfilled and the incidence of preterm-PE was 5.17%; in those screen-positive and screen-negative by the FMF algorithm the incidence of preterm-PE was 8.71% and 0.65%, respectively and the RI was 0.075. In 2,360 (6.8%) pregnancies with ≥2 NICE moderate-risk criteria the incidence of preterm-PE was 1.74%; in those screen-positive and screen-negative by the FMF algorithm the incidence was 4.91% and 0.42%, respectively and the RI was 0.085.
OC10: THE CHALLENGE OF SCREENING IN PREGNANCY: PRE-ECLAMPSIA, IUGR AND PRETERM BIRTH

Conclusions:
In ACOG or NICE screen-positive women that are screen-negative by the FMF algorithm the risk of preterm-PE is reduced to within or below background levels. The results provide further evidence to support risk based screening using biomarkers.
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Implementation of first trimester screening for PE and FGR in low-resource settings S. Lakshmy, T. Ziyaulla, N. Rose Fetal Medicine, Shri Lakshmi Clinic and Scan Centre, Krishnagiri, Tamilnadu, India Objectives: Pre-eclampsia [PE] is a leading cause of perinatal morbidity and mortality and hence is the need to implement an universal screening protocol for PE to identify the truly high risk women who would benefit from aspirin therapy. The impact of PE in developing countries reinforces the need for PE screening with the available resources and the objective of this study is to evaluate the performance and feasibility of different screening protocols in low resource settings. Methods: First trimester screening for PE and fetal growth restriction [ FGR] was done in 6289 cases. Group I included 6289 women whose risk prediction was done by FMF algorithm with maternal characteristics [MC] , mean arterial pressure [MAP] and uterine artery Doppler [UAD] of which 2557 were screen positive. Group II included 2067 women whose risk was predicted with MC, MAP, UAD and PAPP -A of which 602 were screen positive. Group III included 576 women whose risk prediction included all parameters with PLGF of which 24 were positive for early onset PE and 36 for late onset PE.
